Otsuka and Shape Therapeutics: Revolutionizing Ocular Disease Treatments

Shape Therapeutics, a Seattle-based biotech company, announced a new partnership with pharmaceutical entity Otsuka. Their efforts will focus on creating new eye disease treatments with the specific interest of utilizing intravitreal Adeno-Associated Viruses (AAVs).

Otsuka will pay Shape Therapeutics an initial amount to access its existing tools, which will be instrumental in developing treatments. Shape stands to earn nearly $1.5 million in assets if its efforts with Otsuka are successful.

Although it is known for its development of RNA technologies, Shape has begun branching into other areas of discovery. It recently pursued another partnership with Swiss healthcare company Roche to support its efforts in treating rare diseases.

READ THE STORY at The Healthcare Technology Report »